Japan Cardiac Resynchronization Therapy Market Size & Outlook
- MedTech
- Cardiovascular Devices
- Cardiac Resynchronization Therapy Market Outlook
- Cardiovascular Devices
Global Report
Related Markets
Ask a question about the cardiac resynchronization therapy market
Japan cardiac resynchronization therapy market highlights
- The Japan cardiac resynchronization therapy market generated a revenue of USD 194.0 million in 2025 and is expected to reach USD 321.5 million by 2033.
- The Japan market is expected to grow at a CAGR of 6.6% from 2026 to 2033.
- In terms of segment, crt-defibrillator was the largest revenue generating product in 2025.
- CRT-Pacemaker is the most lucrative product segment registering the fastest growth during the forecast period.
Cardiac resynchronization therapy market data book summary
| Market revenue in 2025 | USD 194.0 million |
| Market revenue in 2033 | USD 321.5 million |
| Growth rate | 6.6% (CAGR from 2026 to 2033) |
| Largest segment | Crt-defibrillator |
| Fastest growing segment | CRT-Pacemaker |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CRT-Defibrillator, CRT-Pacemaker |
| Key market players worldwide | Medtronic PLC, Abbott Laboratories, Boston Scientific Corp, BIOTRONIK, MicroPort Scientific Corp, LivaNova PLC |
Other key industry trends
- In terms of revenue, Japan accounted for 3.8% of the cardiac resynchronization therapy market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, Japan cardiac resynchronization therapy market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 253.0 million by 2033.
Asia Pacific’s market growth is being spearheaded by Japan, owing to high penetration of CRT devices, rapidly aging population, and supportive government policies. A 2020 study published in Journal of Arrhythmia analyzed data from 2006 to 2016 extracted from Japan Cardiac Device Treatment Registry (JCDTR).
The number of patients that received ICD implants, CRT-D implants, and CRT-P implants were found to be 17,564, 9,470, & 1,087, respectively. In July 2017, Biotronik launched Evity CRT-P in the Japanese market. The product featured battery life of almost 10 years, MRI AutoDetect, RF Telemetry, and BIOTRONIK Home Monitoring. Such initiatives by key companies are anticipated to fuel the market.
No credit card required*
Publish Date: Nov 11, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cardiac Resynchronization Therapy Market Scope
Cardiac Resynchronization Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Medtronic PLC | View profile | 95,000 | Lower Hatch Street, 20 On Hatch, Dublin, Ireland, 2 | www.medtronic.com |
| Boston Scientific Corp | View profile | 48,000 | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 | www.bostonscientific.com |
| LivaNova PLC | View profile | 2,900 | 20 Eastbourne Terrace, London, United Kingdom, W2 6LG | www.livanova.com |
| BIOTRONIK | View profile | 5001-10000 | Berlin, Berlin, Germany, Europe | www.biotronik.com/de-de |
| MicroPort Scientific Corp | View profile | 8,230 | 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai, China, People's Republic of, 201203 | www.microport.com |
Japan Cardiac Resynchronization Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cardiac Resynchronization Therapy Market Outlook will help companies and investors design strategic landscapes.
Crt-Defibrillator was the largest segment with a revenue share of 55.93% in 2025.
Horizon Databook has segmented the Japan cardiac resynchronization therapy market based on crt-defibrillator, crt-pacemaker covering the revenue growth of each sub-segment from 2021 to 2033.
Asia Pacific’s market growth is being spearheaded by Japan, owing to high penetration of CRT devices, rapidly aging population, and supportive government policies. A 2020 study published in Journal of Arrhythmia analyzed data from 2006 to 2016 extracted from Japan Cardiac Device Treatment Registry (JCDTR).
The number of patients that received ICD implants, CRT-D implants, and CRT-P implants were found to be 17,564, 9,470, & 1,087, respectively. In July 2017, Biotronik launched Evity CRT-P in the Japanese market. The product featured battery life of almost 10 years, MRI AutoDetect, RF Telemetry, and BIOTRONIK Home Monitoring. Such initiatives by key companies are anticipated to fuel the market.
- Japan Cardiac Resynchronization Therapy Market Product Outlook (Revenue, USD Million , 2021-2033)
- CRT-Defibrillator
- CRT-Pacemaker
- Japan Cardiac Resynchronization Therapy Market End-Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Cardiac Centers
- Others
Reasons to subscribe to Cardiac Resynchronization Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cardiac Resynchronization Therapy Market Outlook databook
- Our clientele includes a mix of Cardiac Resynchronization Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Cardiac Resynchronization Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Cardiac Resynchronization Therapy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Japan Cardiac Resynchronization Therapy Market, 2021-2033 (US$M)
Japan cardiac resynchronization therapy market statistics, by product, 2021-2033 (US$M)
